Loading
Genetic Predisposition / Pheochromocytoma / Paraganglioma · Interventional Study
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered but ongoing pragmatic randomized controlled trial evaluating behavioural nudge strategies (directed at clinicians and/or patients) to increase genetic testing rates across a diverse health system. The study leverages EHR infrastructure and implementation science informed by behavioural economics. No efficacy or safety results are reported in this registry record.
Interventional, Randomized, Factorial, Quadruple masking, Health Services Research purpose. Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy N…; age from 18 Years. Intervention: Generic BPA; no nudge; Clinician nudge, order; Clinician nudge, refer; Patient nudge; Clinician BPA order plus patient nudge; Clinician BPA refer plus patient nudge. n = 1,000. 1 site: United States.
This is a registered but ongoing pragmatic randomized controlled trial evaluating behavioural nudge strategies (directed at clinicians and/or patients) to increase genetic testing rates across a diverse health system. The study leverages EHR infrastructure and implementation science informed by behavioural economics. No efficacy or safety results are reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Results, when available, will inform implementation strategies for scaling genomic medicine delivery beyond traditional genetic counselling. This trial represents an early application of behavioural economics to increase genetic testing uptake in clinical practice.
This is a study registration describing a planned interventional trial with no results reported; it documents design, rationale, and methodology for a behavioural nudge intervention to increase genetic testing rates, but outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Results, when available, will inform implementation strategies for scaling genomic medicine delivery beyond traditional genetic counselling. This trial represents an early application of behavioural economics to increase genetic testing uptake in clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06377033). This is a study registration, not published results. Lead sponsor: University of Pennsylvania. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 1000 participants (ESTIMATED). Conditions: Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm. Interventions: BEHAVIORAL: Behavioral nudge. Primary outcome measures: Rate of Genetic Testing , 3 years. Brief summary: Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place. Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.